Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135467 | 0.85 | ALDH1A1 (0.41) | LMNAALDH1A1HSD17B10THRB | |
| SCHEMBL28217628 | 0.78 | ALDH1A1 (0.36) | LMNAALDH1A1HSD17B10THRB | |
| SCHEMBL28376452 | 0.76 | LMNA (0.35) | LMNAALDH1A1HSD17B10THRB | |
| SCHEMBL5838168 | 0.76 | ALOX15 (0.39) | LMNAALDH1A1HSD17B10THRB | |
| SCHEMBL28150415 | 0.76 | ALDH1A1 (0.35) | LMNAALDH1A1HSD17B10THRB | |
| SCHEMBL28961945 | 0.76 | LMNA (0.35) | LMNAALDH1A1HSD17B10THRB | |
| SCHEMBL28211317 | 0.76 | ALDH1A1 (0.35) | LMNAALDH1A1HSD17B10THRB | |
| SCHEMBL11369214 | 0.76 | ALDH1A1 (0.46) | LMNAALDH1A1HSD17B10THRB | |
| SCHEMBL27282353 | 0.74 | ALDH1A1 (0.34) | LMNAALDH1A1HSD17B10 | |
| SCHEMBL3344718 | 0.74 | THRB (0.40) | LMNAALDH1A1HSD17B10THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078401-B2 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-18 | — | — | US | claimed |
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC | 2005-01-27 | — | — | US | claimed |
| US-7078401-B2 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | TBXA2R, MRGPRX2, MRGPRX1 | LMNA 4165/4885ALDH1A1 2523/4885HSD17B10 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.